Pharnext S.A.
Pharnext to Present PXT864 Data at the Alzheimer’s Association International Conference 2017
DGAP-News: Pharnext S.A. / Key word(s): Conference Pharnext to Present PXT864 Data at the Alzheimer’s Association International Conference 2017
Paris, France, 5:45pm, July 10, 2017 (CEST) – Pharnext SA (FR00111911287 – ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that data related to PXT864, the Company’s lead PLEODRUG(TM), in development for the treatment of Alzheimer’s disease (AD), will be presented in two posters at the Alzheimer’s Association International Conference 2017 (AAIC), July 16-20, in London, England. Details are as follow:
PXT864 is a novel synergistic combination of baclofen and acamprosate given as a pill twice-daily. PXT864 acts through a new mechanism of action that targets metabolic imbalance in the brain of patients suffering from neurodegenerative diseases. PXT864’s most advanced indication is Alzheimer’s disease. Development in other neurodegenerative diseases, including Parkinson’s disease and amyotrophic lateral sclerosis (ALS), is also planned. About Pharnext CONTACTS
10.07.2017 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |